White blood cell subsets in HER2-positive breast cancer patients treated with trastuzumab in relation to clinical outcome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

White blood cell subsets in HER2-positive breast cancer patients treated with trastuzumab in relation to clinical outcome

Published:2021-08 Issue: Volume:224 Page:153543
ISSN:0344-0338
Container-title:Pathology - Research and Practice
language:en
Short-container-title:Pathology - Research and Practice

Author:

Matić Ivana Z.,Grujić Milica,Kolundžija Branka,Damjanović Ana,Tomašević Zorica,Đorđić Crnogorac Marija,Džodić Radan,Filipović Lješković Ivana,Ždrale Zdravko,Erić-Nikolić Aleksandra,Juranić Zorica

Funder

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja

Publisher

Elsevier BV

Subject

Cell Biology,Pathology and Forensic Medicine

Reference36 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018;Ferlay;Eur. J. Cancer,2018

2. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

3. Trastuzumab: updated mechanisms of action and resistance in breast cancer;Vu;Front Oncol.,2012

4. Activity and resistance of trastuzumab according to different clinical settings;Tagliabue;Cancer Treat. Rev.,2012

5. Molecular determinants of trastuzumab efficacy: what is their clinical relevance?;De;Cancer Treat. Rev.,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP